Christine Miller is President/CEO, Melinta Therapeutics where she is accelerating its transformation and redefining the portfolio strategy from pure play antibiotics to become a leader in the hospital acute care space. Christine has ensured the FDA approval for KIMYRSA™ (Oritavancin) and REZZAYO™ (rezafungin for injection). She has also secured 3 partnerships: in-licensing of rezafungin from Cidara Therapeutics for exclusive commercialization in the US; licensing agreements to commercialize anti-infectives in Canada with Xedition and Middle East and North America with Hikma. Christine held progressive leadership roles culminating in Global Head of Portfolio – Enterprise at Sandoz, a division of Novartis. She managed the company’s global and US product portfolio and has been involved in 20 different product acquisitions; has launched more than 50 new products. Christine is Board Chair of the Antimicrobials Working Group (AWG). She also serves on the board of BioNJ and recently completed service as a Board Director for biopharma company, Iveric Bio. Christine earned a BA in Chemical Engineering from Rensselaer Polytechnic Inst., holds an MBA in Technology from Stevens Institute of Technology.
